Provided by Tiger Trade Technology Pte. Ltd.

Moleculin Biotech

2.44
+0.01000.41%
Post-market: 2.20-0.2400-9.84%19:55 EDT
Volume:83.88K
Turnover:198.93K
Market Cap:13.02M
PE:-0.09
High:2.44
Open:2.44
Low:2.34
Close:2.43
52wk High:28.61
52wk Low:1.79
Shares:5.34M
Float Shares:4.89M
Volume Ratio:0.68
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-28.4200
EPS(LYR):-158.0236
ROE:-256.05%
ROA:-80.35%
PB:0.87
PE(LYR):-0.02

Loading ...

Moleculin Biotech Raises $6.8 Million Through Warrant Exercises

Reuters
·
Dec 10, 2025

Moleculin Biotech Nears First Unblinding in Pivotal Phase 3 AML Trial

Reuters
·
Dec 09, 2025

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “Miracle” Phase 3 Aml Trial on Pace for Q1 2026

THOMSON REUTERS
·
Dec 09, 2025

Moleculin Biotech Partners with CIC biomaGUNE to Study Annamycin for Brain Tumors

Reuters
·
Dec 08, 2025

Moleculin Announces New Annamycin Collaboration in Brain Tumors

THOMSON REUTERS
·
Dec 08, 2025

Moleculin Biotech Inc - Enters Research Agreement With Cic Biomagune

THOMSON REUTERS
·
Dec 08, 2025

Moleculin Biotech trading halted, news pending

TIPRANKS
·
Nov 29, 2025

Moleculin Biotech Enacts 1-for-25 Reverse Stock Split

Reuters
·
Nov 29, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Nucor, Natgas companies, health insurers

Reuters
·
Nov 27, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Robinhood Markets, Oracle, Grindr

Reuters
·
Nov 26, 2025

BUZZ-Moleculin Biotech falls after reverse stock split move

Reuters
·
Nov 26, 2025

Moleculin Biotech Inc - to Effect 1-for-25 Reverse Stock Split December 1

THOMSON REUTERS
·
Nov 26, 2025

Moleculin Biotech Appeals Nasdaq Delisting Decision

TIPRANKS
·
Nov 22, 2025

Moleculin Biotech Faces Nasdaq Delisting After Equity Rule Violation

Reuters
·
Nov 22, 2025

Moleculin Biotech Reports Increased Loss Amid Ongoing Trials

TIPRANKS
·
Nov 14, 2025

Moleculin Biotech Nears First Unblinding Milestone in Pivotal Phase 3 AML Trial

Reuters
·
Nov 13, 2025

Moleculin Reports 60% of First 45 Subjects in Pivotal “Miracle” Phase 3 Aml Trial Consented

THOMSON REUTERS
·
Nov 13, 2025

Moleculin Biotech’s Strategic Advancements and Potential in Oncology: Buy Rating Justified by Key Partnerships and Promising Trials

TIPRANKS
·
Nov 13, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Floor & Decor, Starbucks, gold miners

Reuters
·
Nov 12, 2025

Moleculin Biotech Partners with UNC for Cancer Research

TIPRANKS
·
Nov 12, 2025